WallStSmart

Evotec SE ADR (EVO)vsViatris Inc (VTRS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1950% more annual revenue ($14.73B vs $718.32M). VTRS leads profitability with a -4.1% profit margin vs -25.2%. EVO appears more attractively valued with a PEG of 1.42. EVO earns a higher WallStSmart Score of 42/100 (D).

EVO

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.38

VTRS

Hold

40

out of 100

Grade: D

Growth: 2.0Profit: 3.5Value: 3.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EVOUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$33.26

Current Price

$1.32

$31.94 discount

UndervaluedFair: $33.26Overvalued
VTRSSignificantly Overvalued (-80.4%)

Margin of Safety

-80.4%

Fair Value

$8.94

Current Price

$19.63

$10.69 premium

UndervaluedFair: $8.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

VTRS1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

EVO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$600.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-28.6%2/10

ROE of -28.6% — below average capital efficiency

VTRS4 concerns · Avg: 2.0/10
PEG RatioValuation
3.732/10

Expensive relative to growth rate

Return on EquityProfitability
-4.4%2/10

ROE of -4.4% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book.

Bear Case : EVO

The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

EVO carries more volatility with a beta of 1.31 — expect wider price swings.

EVO is growing revenue faster at 0.6% — sustainability is the question.

VTRS generates stronger free cash flow (814M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EVO scores higher overall (42/100 vs 40/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?